Brainsway gets FDA approval to begin bipolar disorder trial
Brainsway has received investigational device exemption approval from the US Food and Drug Administration (FDA) to initiate a multicentre clinical trial to investigate the efficacy of its deep transcranial magnetic stimulation device as a treatment for bipolar disorder.
Brainsway has received investigational device exemption approval from the US Food and Drug Administration (FDA) to initiate a multicentre clinical trial to investigate the efficacy of its deep transcranial magnetic stimulation device as a treatment for bipolar disorder.
The device enables non-invasive depolarisation or hyperpolarisation of brain neurons.
Medical Device Network Excellence Awards - Nominations Closed
Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact
Excellence in Action HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis Systemand leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.
